Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teprotumumab N01 vs IVGC in Active Thyroid Eye Disease
NCT07265258Phase 4Recruiting
- Sponsor
- Innovent Biologics
- Start
- Jul 2026
- Primary completion
- Jun 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of teprotumumab in thyroid eye disease (TED), sponsored by Innovent Biologics. Started Jul 2026; status: recruiting.
02
Drugs
teprotumumab
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT07265258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07265258.